Ketamine Shows Promise for Severe Obsessive-Compulsive Disorder in New Study
Last reviewed and updated: June 24, 2026.
Key Takeaways
| Mechanism | NMDA glutamate antagonism — completely different from SSRIs; targets CSTC circuit dysregulation central to OCD neurobiology |
| Speed | Y-BOCS reductions within 24–48 hrs of infusion — vs weeks for SSRIs; most rapid anti-OCD effect of any known treatment |
| Durability | Effects typically fade within days–weeks; no established maintenance protocol; combination with ERP therapy under study |
| OCD unresponsive rate | 40–60% of OCD patients have inadequate response to first-line SSRIs + ERP — creating real need for alternatives |
| Clinical access | IV ketamine off-label at ketamine clinics; Spravato NOT approved for OCD; look for OCD-experienced psychiatrists; out-of-pocket cost |
A recent study has uncovered promising findings regarding ketamine as a treatment for severe obsessive-compulsive disorder (OCD). While OCD can be a debilitating condition for many, especially when it resists traditional treatments, this research offers new hope for those struggling with the most severe forms of the disorder.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Exploring the Potential of Ketamine
The study focused on individuals whose OCD symptoms had not responded to conventional therapies. Researchers turned to ketamine, a drug traditionally used as an anesthetic but increasingly explored for its effects on mental health. Previous studies had suggested ketamine’s rapid antidepressant effects, and now its potential for treating severe OCD is coming into focus.
The results were striking. Patients who underwent ketamine infusions experienced significant reductions in OCD symptoms. These improvements were not just short-lived but lasted for several weeks. Such findings offer a crucial alternative for those with limited options left.
Here’s a Breakdown of the Study
| Aspect | Details |
|---|---|
| Study Design | Randomized double-blind, active-controlled crossover study |
| Sample Size | 12 participants recruited, 10 completed the study (7 females, 3 males) |
| Age Range | 23–49 years (mean age 33 years) |
| Primary Outcome Measure | Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) |
| Control Drug | Fentanyl 50 µg (psychoactive control) |
| Treatment Doses | Ketamine 0.5 mg/kg, 1.0 mg/kg |
| Duration of Effect | Maximal Y-BOCS score reduction observed 1–2 hours post-dose, with some effects lasting up to 168 hours |
| Key Results | Ketamine doses (both 0.5 mg/kg and 1.0 mg/kg) showed greater reductions in Y-BOCS compared to fentanyl |
| Response Rate | 60% response rate for ketamine 0.5 mg/kg at 24 hours, 18% for ketamine 1.0 mg/kg, 10% for fentanyl |
| Adverse Events | Dissociative symptoms (e.g., blurred vision, lightheadedness, numb lips) reported after ketamine doses |
| Safety Concerns | Two participants dropped out due to dissociative side effects from the 1.0 mg/kg dose |
| Cardiovascular Effects | Blood pressure changes were observed but normalized within 60 minutes |
| Tolerability | Higher dissociative symptoms with 1.0 mg/kg ketamine, moderate effects with 0.5 mg/kg ketamine |
| Conclusions | Ketamine showed promise for short-term efficacy in treatment-resistant OCD, but further studies on dosing and long-term effects are needed |
Why This Study Matters
For individuals with severe OCD, daily life can become overwhelming. Common treatments, including selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT), may not be effective for everyone. The limitations of these therapies are a driving force behind the search for new treatments. This study positions ketamine as a possible game-changer in providing relief to those for whom current treatments fall short.
Researchers have long been interested in ketamine’s ability to influence brain chemistry, particularly its effects on glutamate, a neurotransmitter involved in mood regulation. The study supports the idea that ketamine’s ability to restore balance in the brain could be key in alleviating symptoms of severe OCD.
Looking Ahead
As with any promising treatment, the journey to widespread use remains complex. Additional studies are necessary to determine optimal dosage, long-term effects, and whether ketamine could become a standard treatment option. However, the new research offers hope to those who may have felt trapped by their condition. For now, it opens a door to a future where severe OCD may not have to dominate lives.
Related provider: KetaMIND Hillcrest ‘ Hillcrest, KwaZulu
Ketamine for OCD in 2025: Where the Research Stands and What It Means for Patients
Obsessive-compulsive disorder is one of the most treatment-resistant psychiatric conditions — roughly 40–60% of patients have inadequate response to first-line treatments (SSRIs + ERP therapy). Ketamine’s glutamate mechanism offers a genuinely different pathway than existing OCD treatments.
Why ketamine, why OCD? First-line OCD treatments target the serotonin system (SSRIs at high doses) and behavioral pathways (Exposure and Response Prevention therapy). These work for many patients, but a substantial minority remain severely symptomatic. Ketamine works primarily through NMDA glutamate receptor antagonism — a completely different mechanism from SSRIs. This is significant because glutamate dysregulation in cortico-striato-thalamo-cortical (CSTC) circuits is a well-established feature of OCD neurobiology. Ketamine’s rapid effects on these circuits — demonstrable within hours — contrast sharply with SSRIs, which require weeks of treatment to take effect. This suggests ketamine may work through a pathway that SSRIs cannot reach, offering hope for patients who have not responded to serotonin-based treatment.
What the study found and what it doesn’t mean. The studies on ketamine for OCD have generally shown rapid, meaningful Y-BOCS (Yale-Brown Obsessive Compulsive Scale) score reductions following ketamine infusions — often within 24–48 hours of administration. This rapid response is highly unusual for OCD, where even effective treatments typically take weeks to months to show results. However, the durability question is important: ketamine’s anti-OCD effects appear to fade over days to weeks without repeat dosing, similar to its antidepressant effects. No maintenance dosing protocol for OCD has been established. Current research is examining whether repeated infusions, extended dosing intervals, or combination with ERP therapy can produce more durable outcomes.
Clinical availability for OCD: what to know. IV ketamine is legally available off-label at ketamine clinics nationally. However, OCD is not one of the most commonly treated conditions at ketamine clinics — most clinics focus on treatment-resistant depression (TRD) and PTSD as their primary indications. Patients with severe treatment-resistant OCD interested in ketamine should look for clinics with psychiatrists experienced in OCD management, as dosing protocols and integration support for OCD may differ from standard depression protocols. Spravato (esketamine) is FDA-approved only for TRD and MDD with suicidal ideation — not for OCD — so insurance coverage for OCD treatment with ketamine is unlikely.
Frequently Asked Questions
How does ketamine help OCD?
Ketamine helps OCD through a different mechanism than any existing OCD treatment: NMDA glutamate receptor antagonism. OCD involves dysregulation of cortico-striato-thalamo-cortical (CSTC) circuits, which are glutamatergic pathways. Ketamine appears to rapidly modulate these circuits, producing measurable Y-BOCS score reductions within 24–48 hours — far faster than SSRIs (weeks) or ERP therapy. This speed suggests ketamine reaches a neurobiological pathway that serotonin-targeting treatments cannot. The limitation is durability: effects typically fade within days to weeks without maintenance dosing, and no established maintenance protocol exists yet.
How long does ketamine’s effect on OCD last?
Current research suggests ketamine’s anti-OCD effects typically last days to several weeks following a single infusion or a short series of infusions — shorter than most patients would need for meaningful quality-of-life improvement. This is similar to the durability pattern seen with ketamine for depression, where effects often last 2–4 weeks after a standard series of 6 infusions. For OCD, the durability picture is less established because fewer trials have been conducted. Researchers are studying repeated infusions, extended intervals, and combination with Exposure and Response Prevention therapy as strategies to extend benefit. An important open question is whether early ketamine response can make patients more receptive to ERP therapy, potentially producing more durable outcomes through combined treatment.
What treatments are used for OCD?
First-line OCD treatments: (1) SSRIs at high doses — fluvoxamine, sertraline, fluoxetine, paroxetine, and clomipramine (a TCA) are FDA-approved for OCD; higher doses than used for depression are typically needed; response takes 8–12 weeks; (2) Exposure and Response Prevention (ERP) therapy — the gold-standard psychotherapy for OCD; structured exposure to feared triggers with prevention of compulsive response; highly effective but requires skilled therapist and patient commitment; (3) Combination of SSRI + ERP — often more effective than either alone. For treatment-resistant OCD: augmentation strategies (antipsychotics, d-cycloserine), deep brain stimulation (FDA-approved for refractory OCD), and experimental approaches including ketamine and psilocybin (in early research). Roughly 40–60% of OCD patients have inadequate response to first-line treatments.
Can I get ketamine for OCD at a ketamine clinic?
Potentially yes — IV ketamine is legally available off-label for any condition at licensed ketamine clinics, and OCD is within the range of psychiatric conditions some clinics treat. However: (1) Most ketamine clinics specialize in treatment-resistant depression; OCD protocols may not be as refined; (2) Look for clinics with psychiatrists experienced specifically in OCD, not just ketamine administration; (3) Spravato (FDA-approved esketamine) is approved only for TRD and suicidal ideation — NOT OCD; insurance coverage for OCD is unlikely; IV ketamine for OCD would be out-of-pocket; (4) A referral from your psychiatrist or OCD specialist is useful for evaluating candidacy. The field is moving — more OCD-specific ketamine protocols are being developed as research advances.
